StockData
BridgeBio Oncology Therapeutics, Inc. logo

BridgeBio Oncology Therapeutics, Inc. (BBOT) stock

BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$2.14−0.21 (-8.94%)

Close on Nov 13, 2026Market cap $171.57MP/E –Yield –

Earnings

BridgeBio Oncology Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 4, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.43
-$1.03 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of BridgeBio Oncology Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 4, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026after the close––-$0.43Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026after the close–––Release
Q1 FY2026ended Mar 31, 2026May 12, 2026after the close––-$526.11Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026after the close––-$0.49Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025after the close––-$1.03Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

BridgeBio Oncology Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When BridgeBio Oncology Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases BridgeBio Oncology Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
    Results
  2. BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
    News
  3. Corporate Update September 2026 BBOT Next-Generation RAS-Pathway
    News
  4. BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
    Results
  5. BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
    Results
  6. BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as
    Update
  7. BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
    Results
  8. BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and
    News
  9. BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
    Results
  10. THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF BBOT AS OF JUNE 30, 2025 AND FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024
    Update
  11. THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF PUBCO AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND FOR THE YEAR ENDED DECEMBER 31, 2024
    Update
  12. MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF BBOT FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024
    Update
  13. PRESS RELEASE, DATED AUGUST 6, 2025
    Update
  14. PRESS RELEASE, DATED JULY 11, 2025
    Update
  15. PRESS RELEASE, DATED FEBRUARY 28, 2025
    Update

See a number that looks wrong?